US Broker Ratings

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Exploring a 41.95% Potential Upside in the Biotech Sector

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) stands out in the healthcare sector with its innovative approach to tackling chronic endocrine and neurological diseases. This Chicago-based biopharmaceutical company has captured attention..

Akebia Therapeutics (AKBA): Analyzing 235% Potential Upside in the Healthcare Sector

For investors with an eye on the healthcare sector, Akebia Therapeutics, Inc. (NASDAQ: AKBA) presents a compelling case for potential portfolio growth. With a market capitalization of $427.24 million, this..

Replimune Group, Inc. (REPL)

⚠️ No article content returned.

..

Delcath Systems, Inc. (DCTH) Investor Outlook: Assessing a Potential 120% Upside

Delcath Systems, Inc. (NASDAQ: DCTH) is catching the eye of investors with a striking potential upside of 120.84%. This New York-based healthcare company is at the forefront of interventional oncology,..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a 517.98% Potential Upside in Biotech Innovations

Anavex Life Sciences Corp. (NASDAQ: AVXL), a promising player in the biotechnology sector, has piqued the interest of investors with an astonishing potential upside of 517.98%. This New York-based biopharmaceutical..

Beta Bionics, Inc. (BBNX) Investor Outlook: Strong Buy Ratings and Growth Potential in the Healthcare Sector

Beta Bionics, Inc. (NASDAQ: BBNX) is making waves in the healthcare sector with its innovative solutions aimed at improving the lives of individuals with diabetes. Specializing in medical devices, the..

Community Health Systems, Inc. (CYH) Stock Analysis: Evaluating a 25% Potential Upside

Community Health Systems, Inc. (NYSE: CYH), a key player in the healthcare sector, operates a network of general acute care hospitals throughout the United States. Despite the inherent volatility in..

Arcus Biosciences (RCUS) Investor Outlook: Analyzing a Potential 34.7% Upside Amid Biotech Volatility

Arcus Biosciences, Inc. (NASDAQ: RCUS), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its promising portfolio of cancer therapies. Based in Hayward, California, Arcus is focused..

Immatics N.V. (IMTX) Stock Analysis: Unveiling a 78% Potential Upside in Revolutionary Cancer Therapies

In the ever-evolving biotechnology landscape, Immatics N.V. (NASDAQ: IMTX) stands out as a beacon of innovation and potential. This German-based clinical-stage biopharmaceutical company focuses on pioneering T cell redirecting immunotherapies,..

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating Growth with a 15.1% Revenue Surge

InnovAge Holding Corp. (NASDAQ: INNV), a prominent player in the healthcare sector specializing in medical care facilities, is capturing investor attention with its impressive revenue growth of 15.1%. As a..

InMode Ltd. (INMD) Stock Analysis: Unpacking a 13% Potential Upside in the Medical Devices Sector

InMode Ltd. (INMD), an Israel-based leader in the healthcare sector, specializes in innovative medical devices, particularly those leveraging minimally invasive technologies. With a market capitalization nearing $1 billion, InMode has..

Ardelyx, Inc. (ARDX) Investor Outlook: Analyzing the 100% Potential Upside and Strong Buy Ratings

Ardelyx, Inc. (NASDAQ: ARDX) is capturing the attention of investors with its promising pipeline in the biotechnology sector. Specializing in the development and commercialization of innovative therapies for unmet medical..

Embecta Corp. (EMBC) Stock Analysis: Evaluating a 40% Potential Upside in the Medical Devices Market

Embecta Corp. (EMBC), a stalwart in the healthcare sector, stands at a crucial juncture for investors seeking opportunities in the medical instruments and supplies industry. With a current market capitalization..

Cronos Group Inc. (CRON) Stock Analysis: Navigating the Challenges with a Global Cannabis Player

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the burgeoning cannabis sector, has captured the attention of investors with its position in the global market and its recent stock..

Zymeworks Inc. (ZYME) Stock Analysis: Unpacking the 34.97% Potential Upside for Biotechnology Investors

Zymeworks Inc. (NASDAQ: ZYME) stands out in the biotechnology sector with its innovative approach to developing biotherapeutics for cancer and autoimmune and inflammatory diseases. As a clinical-stage company, Zymeworks is..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Look at the 52% Potential Upside

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company specializing in central nervous system (CNS) disorders, is capturing investor interest with its significant potential upside of 52.38%. As the..

SI-BONE, Inc. (SIBN) Stock Analysis: Exploring a 31% Upside Potential in the Healthcare Sector

Investors seeking opportunities in the healthcare sector should take a closer look at SI-BONE, Inc. (NASDAQ: SIBN), a medical device company specializing in innovative solutions for musculoskeletal disorders. With a..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Unveiling a Potential 235% Upside in the Biotech Sector

LENZ Therapeutics, Inc. (NASDAQ: LENZ) presents a unique opportunity for investors seeking to capitalize on the rapidly evolving biotechnology sector. Headquartered in Solana Beach, California, this biopharmaceutical company is making..

Pharvaris N.V. (PHVS) Stock Analysis: Assessing a 66.61% Potential Upside in the Biotech Sector

Pharvaris N.V. (PHVS), a Switzerland-based biopharmaceutical company, has been making waves in the biotechnology industry with its promising developments in therapies for rare diseases. Specializing in the treatment of angioedema..

STAAR Surgical Company (STAA) Stock Analysis: Navigating Growth with 15% Upside Potential

STAAR Surgical Company (NASDAQ: STAA) presents a captivating investment opportunity within the healthcare sector, specifically in the medical instruments and supplies industry. With a market capitalization of $1.14 billion, this..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds